Low Anterior Resection Syndrome (LARS)

Rather than a true surgical complication, LARS is a consequence of low anterior resection and coloanal anastomosis (see Total Mesorectal Excision (TME) & Sphincter-Sparing Resection) — a syndrome, not a technical failure. Content below is from textbook reference chapters (Sabiston Ch52 - Rectal Cancer Surgery, ASCRS Ch29 - Proctectomy for Rectal Cancer, and ASCRS Ch62 - Low Anterior Resection Syndrome, the dedicated LARS chapter), not primary literature.

Definition and incidence

May be present in up to 80% of patients undergoing low anterior resection. Characterized by a mixture of multiple symptoms: frequency, multiple fragmented bowel movements, a sensation of incomplete emptying, incontinence, constipation, and diarrhea. Most symptoms improve 1 year or more after resection, but long-term dysfunction is described in the majority of patients. Studies have shown that when less than 4cm of native rectum is left in situ following low anterior resection, there is loss of rectal reservoir function and significant alteration in bowel function.

Chronicity data (per ASCRS Ch62 - Low Anterior Resection Syndrome): as many as 58% of patients report major LARS symptoms (urgency, frequency, clustering) at 3 months post-LAR/restorative proctectomy; 46% still have major symptoms at 12 months; and 41% still have them at 54 months — implying LARS can genuinely be lifelong for a substantial subset of patients, not just a transient postoperative phase. Research on LARS specifically has been hampered by the historical lack of a uniform definition, making meta-analyses/systematic research difficult prior to the Delphi consensus below.

Notably, LARS is not simply synonymous with incontinence: even among patients who retain most or all of their rectum, 85% maintain continence, yet 42% still meet criteria for LARS — underscoring that LARS is a broader bowel-dysregulation syndrome, not solely a sphincter-competence problem. LARS-like bowel dysfunction has also been reported in patients with a preserved rectum who underwent definitive pelvic chemoradiotherapy for other cancers (most described in women treated for cervical or anal squamous cell carcinoma) — up to 50% report major bowel-symptom impact on quality of life, suggesting radiation-driven pelvic floor/neural injury can produce a LARS-like picture independent of any rectal resection.

Formal Delphi consensus definition, per ASCRS Ch29 - Proctectomy for Rectal Cancer: initially described as "disordered bowel function after rectal resection" or "anterior resection syndrome" — including fecal incontinence, incomplete evacuation, clustering of bowel movements, straining, and discomfort — first thought to be transient but now known to potentially persist indefinitely (improvement, when it occurs, tends to plateau around 2 years post-resection). A Delphi consensus among multiple healthcare societies, incorporating surgeon, patient, and other healthcare-worker perspectives, broadened and better defined the symptoms/consequences of what is now termed "low anterior resection syndrome" (LARS). Eight symptoms and eight consequences were agreed upon; a patient must have at least one of each to meet the consensus definition of having LARS. (Note: ASCRS Ch62 - Low Anterior Resection Syndrome, citing the same Delphi consensus (325 experts including 156 patients with LARS), describes it as "eight symptoms and five consequences" — its own figure appears to enumerate more than five distinct consequence items, so this looks like a transcription inconsistency somewhere upstream of the wiki rather than a genuine second consensus count; flagged here rather than silently resolved.)

Symptoms: variable and unpredictable bowel function, emptying difficulties, altered stool consistency, urgency, increased stool frequency, repeated painful bowel movements, incontinence, and soiling.
Consequences: toilet dependence, preoccupation with bowel function, dissatisfaction with bowel habits, strategies/compromises to manage symptoms, and adverse impact on mental/emotional well-being, social and daily activities, relationships and intimacy, and roles/commitments/ responsibilities.

The LARS score

Per ASCRS Ch29 - Proctectomy for Rectal Cancer — resolves this page's own previously-flagged open item ("no specific LARS score/questionnaire detail"): severity of LARS can be quantified with the LARS score, initially described in 2012. It uses five questions/items — incontinence for flatus, incontinence for liquid stools, clustering (of bowel movements), frequency, and urgency — scored to a composite total from 0 to 42. A score of 0–20 is not consistent with LARS; 21–29 equates with "minor LARS"; and 30–42 equates with "major LARS." Other scoring systems, such as the Bowel Function Instrument (BFI) created by Memorial Sloan Kettering Cancer Center, haven't been as widely adopted despite being more comprehensive than the LARS score.

Cause

Multifactorial, and per ASCRS Ch62 - Low Anterior Resection Syndrome genuinely poorly understood — none of the proposed mechanisms have been properly studied or validated. Proposed contributors include: injury of the internal sphincter, loss of sensitivity in the anorectal mucosa, loss or impairment of the rectoanal-inhibitory reflex, reduction in the capacity of the rectal reservoir, loss of compliance of the transposed colon, autonomic denervation, an increase in colonic motility, and radiotherapy-related damage to rectal mucosa.

Risk factors for LARS after LAR, per Ch62: age, female sex, tumor location closer to the anal verge, extent of mesorectal dissection, use of neoadjuvant pelvic radiation, and having a diverting loop ileostomy. Incidence is higher in patients undergoing TME, those with a coloanal anastomosis, those who received neoadjuvant chemoradiation, and those who had an anastomotic leak (see Colorectal Anastomotic Complications) — i.e. the same factors that make for a more difficult, lower resection also predispose to worse functional outcomes afterward. A plausible mechanism for the leak association, per that page's ASCRS Ch10 content: chronic pelvic fibrosis from leak-related inflammation may itself reduce rectal/neorectal compliance — one of this section's causes above — rather than leak and LARS simply sharing upstream risk factors.

Prediction and preoperative counseling

The online POLARS (Preoperative LARS) nomogram (Battersby et al.) helps predict LARS risk before restorative proctectomy, supporting informed consent that goes beyond perioperative complications to include projected bowel dysfunction. When patients understand the true risk of fecal urgency and other bowel problems that may dominate daily life, some opt for an end colostomy instead — an honest discussion of that option should be offered to all patients being considered for restorative resection, not only those with baseline bowel dysfunction or mobility limitations.

Prevention

Technical mechanisms currently used to reduce LARS symptoms, by increasing the capacity of the neorectum:

Anastomosis with a 5–6 cm colonic J-pouch.
Transverse coloplasty, or a side-to-end colorectal anastomosis.

Coloplasty is a possible alternative in obese patients in whom a J-pouch doesn't fit into the narrow pelvis: a 10-cm longitudinal colotomy is made about 5 cm from the distal end of the transposed colon, then sutured transversely to widen the colon and increase its compliance.

Anastomotic Construction (ASCRS Ch9) adds outcome-comparison detail partially filling this page's "no head-to-head data" open item below: a colonic J-pouch shows functional advantage over a straight anastomosis persisting to 5 years in some series (others find convergence by 2 years); an ACS-NSQIP study found J-pouch associated with fewer reoperations and less organ/space infection than straight anastomosis, at the cost of higher ICU usage; the side-to-end ("STE"/Baker-type) anastomosis compares favorably to J-pouch on function and leak rate and may be faster to construct. Even with a colonic reservoir, up to 30% of patients may still experience increased frequency/ urgency — a reservoir does not eliminate LARS risk, it mitigates it. A more cautious note from Ch62: while short-term bowel function favors a colonic J-pouch, by 18 months patient-reported outcomes were not statistically different from a straight end-to-end anastomosis in at least one study — tempering how durable the J-pouch's functional advantage really is. Beyond reservoir choice, no intervention has been definitively proven to prevent LARS; avoiding pelvic radiation where oncologically appropriate, early stoma closure, and mechanical bowel preparation are all under study as possible risk-modifying factors, but none is yet established.

Diagnosis, and excluding LARS-mimicking conditions

Per Ch62: begin questioning patients about bowel function starting around 3 months after intestinal continuity is restored. Before attributing symptoms to LARS itself, exclude correctable LARS-mimicking conditions: pancreatic malabsorption, small intestinal bacterial overgrowth, 5-FU-induced lactose intolerance, radiation enteritis or radiation-induced fat/bile-salt malabsorption, surgical anastomotic strictures, ischemic conduits, and local tumor recurrence. A trial of cholestyramine can help distinguish/manage bile-salt-driven diarrhea. Flexible sigmoidoscopy should be considered in patients with LARS-like symptoms within the first 5 years after surgery — particularly if surveillance has been inadequate or bowel function suddenly worsens — to exclude recurrence, stricture, or another correctable anatomic problem before continuing symptomatic LARS management.

Treatment

Data quality is limited overall — most studies are small, nonrandomized, use varied interventions/ endpoints, and often assess fecal incontinence alone rather than a validated LARS tool. Given this, Ch62 frames LARS as a chronic disease (like diabetes or hypertension) requiring an individualized, multi-modal plan, realistic expectations, and — often — support from gastroenterology, primary care, and mental health colleagues alongside the surgeon. Treatments should be viewed as additive, not replacement: each new intervention is layered onto (not substituted for) what's already working, in a systematic incremental sequence, with precise written instructions and a bowel diary to track response over time (some authors summarize this approach as "Listen, Educate, Treat"). A postoperative systematic screening/treatment protocol at one center dropped mean LARS scores from 31 (major) to 18 (moderate) and cut major-LARS rates from 51.9% to 26.3%; a separate RCT found algorithmic care (vs. routine ad hoc care) improved both symptoms and functional status, regardless of whether it was delivered by a surgeon, gastroenterologist, PCP, or advanced practice provider.

Medical therapy

Begin with dietary fiber and adequate water intake to improve stool consistency, then fiber/bulking supplementation (psyllium), then antidiarrheal/antimotility agents: loperamide (non-opiate, acts locally on intestinal muscle) first, escalating to opiates (atropine/diphenoxylate, tincture of opium) if needed — opiates carry central-nervous-system effects and require longitudinal monitoring as controlled substances, and some patients with a clustering LARS phenotype specifically report worsening symptoms on opioids. If these fail, a trial of amitriptyline (10–25 mg nightly, as tolerated) is reasonable — an open-label fecal incontinence study found an 85% decrease in FI scores with low-dose amitriptyline. Long-term medication use is common and should not itself be considered a treatment failure; patients can be reassured it isn't detrimental. Serotonin (5-HT3) receptor antagonists, extrapolated from FI treatment, have shown only modest effects when trialed in LARS. Probiotics are proposed but poorly supported — a small RCT of VSL#3 after loop ileostomy closure found no effect on LARS symptoms.

Topical/skin care: diarrhea and incontinence-related skin breakdown are common secondary complaints. Zinc- and lanolin-based barrier creams applied to the dentate line, antifungal powder for suspected fungal superinfection, gentle washcloths or a bidet rather than dry/chemical wipes, and short-term topical 2% lidocaine for severe pain are all reasonable adjuncts while the anoderm heals.

Biofeedback / pelvic floor retraining

May provide additional benefit alongside medical therapy, but supporting data is sparse — a systematic review identified only five (mostly small, non-randomized, internationally variable) trials totaling 321 patients, of whom 286 completed the protocol; 4 of 5 showed some improvement in bowel function. A more recent open-label RCT suggested the improvement seen is mostly in the fecal incontinence component specifically, with other LARS domains and the overall LARS score largely unchanged — tempering how much to expect from biofeedback for non-incontinence symptoms. It remains a reasonable option for motivated patients, especially those whose predominant symptom is FI; for patients whose main issue is incomplete emptying, clustering, or fragmentation, stopping after 6–8 sessions without improvement is reasonable.

Retrograde colonic irrigation (RCI)

A frequently used treatment regardless of predominant symptom (fragmentation, clustering, diarrhea, or FI) — not a simple enema. High-volume (500–1000 mL) tepid water is instilled retrograde via a 28 Fr Foley catheter into the neorectum (gravity-fed from a hung bag, e.g. a tube-feeding bag, with a flow regulator) to fill the left colon, then evacuated — a ~30-minute process usually done morning or evening, conditioning the bowel to empty at a predictable time and reducing further movements for the rest of the day (conceptually similar to colostomy irrigation; can be assembled from routine clinic supplies or purchased as a kit, e.g. Peristeen by Coloplast). RCI is well established for FI generally (see Fecal Incontinence), and smaller LARS-specific studies support it too: a 37-patient RCT (RCI vs. PTNS) found RCI reduced maximum daily/nightly stool episodes and improved both LARS and Wexner FI scores; a 27-patient open-label RCT found LARS scores improve from 35 (major) to 12 (mild); another 27-patient series found symptoms recur on discontinuation, and 85% of participants asked to resume RCI after their study ended. A minimum 6-month trial (after successful self-instillation is achieved) is recommended before escalating to more invasive treatment or surgery — this also gives time to optimize medical therapy, complete biofeedback, and let the neorectum adapt.

Sacral neuromodulation (SNM)

First-line for FI not optimized by medical therapy generally (full technique on Fecal Incontinence — test-phase lead placement, then permanent implantation), and increasingly used for LARS specifically. A systematic review of 10 LARS-SNM studies (seven measuring FI improvement, three measuring LARS-score improvement) found 94 patients screened with a test lead, of whom 75 (79.8%) proceeded to permanent implantation, with a median 67.0% improvement in LARS symptoms — lower than SNM's success rate for benign-etiology FI generally, but still clinically meaningful given how few other options exist. Given SNM's minimally invasive nature and built-in test phase, a trial is reasonable in any LARS patient who has failed other options, again as an additive rather than replacement therapy.

Percutaneous tibial nerve stimulation (PTNS)

Emerging LARS-specific data is intriguing, but PTNS is not currently available in the USA for any form of bowel dysfunction — likely reflecting the FDA's concern over contradictory efficacy data, including the CONFIDeNT trial (see Fecal Incontinence), a sham-controlled RCT that found no difference between PTNS and sham stimulation for FI.

Antegrade continence enemas (ACE)

Historically studied mainly in pediatrics (via appendicostomy, Chait/MACE tube, or cecostomy tube), with adult data more limited. A 2016 meta-analysis of 17 observational studies (426 adults with FI and/or constipation, 165 with FI) found a pooled 83.6% success rate (95% CI 75.0–92.1%) at a median 39-month follow-up (a separate systematic review, Patel et al., reached similar conclusions) — both recommend considering ACE in motivated patients before resorting to a permanent colostomy. One French cohort using percutaneous endoscopic cecostomy (PEC) tubes reported 73% success in baseline-FI patients and 90% in post-proctectomy patients, with CCIS improving from 14.3 to 2.7 at 6 months — though scores drifted back up to 10.4 by 2 years. Data on the MACE tube specifically for LARS (as opposed to FI/constipation generally) remains limited and investigational.

Fecal diversion

Last resort after all other options fail. Loop or end, ileostomy or colostomy — fecal diversion reliably restores an acceptable quality of life for patients who have become overwrought with symptoms, even though the decision is daunting to face. An end colostomy is generally preferred when diversion is being considered as a durable solution (being mindful of blood-flow considerations from prior sigmoid/rectal resection); constructing the best possible stoma matters as much as the decision to divert, since the goal is improving quality of life, not trading one poorly functioning system for another.

ASCRS Ch29 - Proctectomy for Rectal Cancer's previously-ingested figures (74% "success rate," 32 of 34 permanently-implanted patients improving) and Ch62's figures above (79.8% proceeding to permanent implant, 67.0% median LARS-symptom improvement) come from different cited systematic reviews/study sets rather than the same study restated — both are retained here as complementary data points from the same overall evidence base rather than reconciled into one number.

Total Mesorectal Excision (TME) & Sphincter-Sparing Resection — the LAR/coloanal-anastomosis procedures that produce this syndrome.
Anastomotic Construction — outcome-comparison data for the J-pouch/side-to-end/coloplasty reservoir options this page's Prevention section covers.
Colorectal Anastomotic Complications — the anastomotic-leak risk factor for LARS noted above.
Fecal Incontinence — full technique detail for sacral neuromodulation, PTNS, and retrograde colonic irrigation, all reused above for LARS management; also the source of the CONFIDeNT sham-controlled PTNS trial referenced in this page's PTNS subsection.
Geriatric Considerations in Colorectal Surgery — ASCRS Ch67 names the LARS score (alongside the Cleveland Clinic Fecal Incontinence Score) as a validated functional-outcome instrument for geriatric patients, and adds an age/frailty-specific decision lens: permanent colostomy may be functionally preferable to coloanal anastomosis in geriatric patients with poor baseline sphincter tone.

Open items / gaps

No primary trial data yet comparing J-pouch vs. coloplasty vs. side-to-end anastomosis outcomes head-to-head — partially addressed by Anastomotic Construction (J-pouch vs. STE comparison), though coloplasty is still not compared to either.
~~No specific LARS score/questionnaire detail.~~ Resolved by ASCRS Ch29 - Proctectomy for Rectal Cancer: the formal Delphi consensus definition and the LARS score (0–42 scale) are now detailed above, along with the BFI alternative.
~~SNS's 74% "success rate" for LARS is reported here as extracted from the chapter's cited systemic review — not independently ingested, and "success" isn't further operationalized in the source.~~ Partially addressed by ASCRS Ch62 - Low Anterior Resection Syndrome's own SNM systematic-review figures (79.8% proceeding to implant, 67.0% median LARS-score improvement), retained alongside rather than merged with the original figure — see the SNS reconciliation subsection above.
The Delphi consensus "consequences" count is inconsistently reported across sources — eight per ASCRS Ch29 - Proctectomy for Rectal Cancer, five per ASCRS Ch62 - Low Anterior Resection Syndrome — flagged in the Definition and incidence section above rather than resolved, since neither chapter's own text unambiguously settles it.
No head-to-head trial comparing RCI, SNM, and PTNS against one another for LARS specifically — each is supported only by its own small, non-comparative studies, so relative effectiveness/sequencing among the three is not evidence-based.

Colorectal LLM Wiki